News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
401,172 Results
Type
Article (23754)
Company Profile (160)
Press Release (377258)
Section
Business (115418)
Career Advice (669)
Deals (19035)
Drug Delivery (69)
Drug Development (47694)
Employer Resources (82)
FDA (11264)
Job Trends (9969)
News (196141)
Policy (17718)
Tag
Academia (2090)
Alliances (33945)
Alzheimer's disease (821)
Approvals (11235)
Artificial intelligence (105)
Bankruptcy (110)
Best Places to Work (8492)
Biotechnology (107)
Breast cancer (95)
Cancer (850)
Cardiovascular disease (72)
Career advice (554)
Cell therapy (174)
Clinical research (38848)
Collaboration (327)
COVID-19 (1829)
C-suite (74)
Data (827)
Diabetes (87)
Diagnostics (4195)
Drug pricing (58)
Earnings (37245)
Employer resources (73)
Events (59159)
Executive appointments (239)
FDA (11673)
Funding (279)
Gene therapy (117)
GLP-1 (353)
Government (2714)
Healthcare (13599)
Infectious disease (1890)
Inflammatory bowel disease (71)
Interviews (94)
IPO (7971)
Job creations (1812)
Job search strategy (511)
Layoffs (186)
Legal (3216)
Lung cancer (149)
Manufacturing (145)
Medical device (10343)
Medtech (10346)
Mergers & acquisitions (11211)
Metabolic disorders (216)
Neuroscience (980)
NextGen Class of 2024 (4500)
Non-profit (3506)
Northern California (869)
Obesity (117)
Opinion (117)
Patents (72)
People (34652)
Phase I (11668)
Phase II (16857)
Phase III (13511)
Pipeline (310)
Policy (65)
Postmarket research (1466)
Preclinical (3887)
Press Release (67)
Radiopharmaceuticals (194)
Rare diseases (147)
Real estate (4412)
Regulatory (12689)
Research institute (1917)
Resumes & cover letters (94)
Southern California (775)
Startups (2316)
United States (8779)
Vaccines (398)
Weight loss (83)
Date
Last 7 days (484)
Last 30 days (2354)
Last 365 days (24227)
2024 (22198)
2023 (26230)
2022 (34782)
2021 (36470)
2020 (35318)
2019 (32542)
2018 (24693)
2017 (21001)
2016 (20282)
2015 (22973)
2014 (16505)
2013 (13552)
2012 (14569)
2011 (14720)
2010 (12419)
Location
Africa (379)
Arizona (86)
Asia (31768)
Australia (3175)
California (1976)
Canada (779)
China (261)
Colorado (102)
Connecticut (111)
Europe (55638)
Florida (297)
Georgia (91)
Illinois (265)
Indiana (155)
Maryland (421)
Massachusetts (1596)
Michigan (105)
Minnesota (199)
New Jersey (718)
New York (679)
North Carolina (509)
Northern California (869)
Ohio (109)
Pennsylvania (530)
South America (566)
Southern California (775)
Texas (306)
Washington State (162)
401,172 Results for "astrazeneca innovation center china".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
China
AstraZeneca’s China Head Taken Into Custody by Chinese Authorities: Reports
While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days after it was reported that he was under investigation for alleged medical insurance fraud in the country.
November 8, 2024
·
2 min read
·
Tristan Manalac
Podcast
AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More
A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an investigation into China exec, the Huntington’s pipeline builds momentum and layoffs continue with Sana Biotechnology and 23andMe.
November 13, 2024
·
1 min read
·
Heather McKenzie
China
AstraZeneca’s Stock Price Takes a Hit as China Chief Investigated for Insurance Fraud
BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” to AstraZeneca, but contends that the share selloff is “overdone” and likely a knee-jerk reaction by investors.
November 6, 2024
·
2 min read
·
Tristan Manalac
Earnings
AstraZeneca Dodges China Questions While Raising 2024 Outlook With Strong Q3 Sales
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the “important” U.S. market.
November 12, 2024
·
3 min read
·
Kate Goodwin
Diabetes
Innovent’s Lilly-Partnered Type 2 Diabetes Drug Aces Phase III in China, Inches Closer to Approval
Innovent Biologics’ dual GLP-1/glucagon receptor agonist mazdutide is also being developed for chronic weight management. China’s regulator accepted Innovent’s drug application for this indication in February 2024.
July 22, 2024
·
2 min read
·
Tristan Manalac
Pharm Country
Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach
Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed a memorandum of understanding with AstraZeneca China to establish a research and development collaboration at AstraZeneca’s Innovation Campus in Chengdu, China.
February 5, 2024
·
4 min read
Policy
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
FibroGen, Inc. announced that FibroGen and AstraZeneca have agreed to terminate the U.S./RoW roxadustat collaboration agreement entered into on July 30, 2013, under which AstraZeneca held development and commercialization rights in the United States and other territories outside of China not licensed to Astellas Pharma Inc.
February 26, 2024
·
4 min read
Cardiovascular disease
AstraZeneca Puts $2B On The Line for Preclinical Heart Disease Drug
For an exclusive license to the preclinical Lp(a) disruptor, AstraZeneca is paying CSPC Pharmaceutical Group $100 million upfront and offering up to $1.92 billion in regulatory and commercial milestones.
October 7, 2024
·
2 min read
·
Tristan Manalac
People
From Argentina to America: A Physician’s Journey to Pharma and AstraZeneca
Carlos Doti has moved countries and changed jobs, but one thing hasn’t changed. Making an impact on patient care has always been a priority for the AstraZeneca executive.
October 10, 2024
·
6 min read
·
Angela Gabriel
Obesity
AstraZeneca Bolsters Obesity Pipeline With Promising Early Data for Candidates
While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb studies and creates a “foothold” for AstraZeneca in the weight loss space.
November 5, 2024
·
3 min read
·
Tristan Manalac
1 of 40,118
Next
